Back to search

Article

Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis?

2024-10-04

Abstract excerpt

Immune-mediated inflammatory diseases like rheumatoid arthritis (RA) have been successfully treated using biologic disease-modifying antirheumatic drugs. These medications are not utilized as first-line treatment, in part because of their high cost, but they are frequently seen to be cost-effective for RA patient populations that do not respond adequately to conventional disease-modifying antirheumatic drugs. More...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c1087b78-6971-53b5-8b62-36ff6e4c8682
DOI
10.12688/f1000research.156983.1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis?DOI 10.12688/f1000research.156983.1
Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis?Semantic proximity
Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 TreatmentSemantic proximity
Continuous effectiveness and safety after a hospital-wide switch to adalimumab biosimilar: an observational study in rheumatoid arthritis patientsSemantic proximity
Comparative real-world retention rate and safety of Biosimilar IBI303 versus Humira in Ankylosing SpondylitisSemantic proximity
Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registriesSemantic proximity
The importance of real-world data in evaluating the safety of biosimilars: a descriptive study of clinical practice in an oncohematological population.Semantic proximity
Molecular Biosimilarity--A Paradigm ShiftSemantic proximity
Ethical and human subject burdens of trials conducted to evaluate biosimilarsSemantic proximity
Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registrySemantic proximity
Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritisSemantic proximity
Factors Affecting Patient Satisfaction Related to Cost and Treatment Effectiveness in Rheumatoid Arthritis: Results From the Multicenter Observational Cohort Study, FRANK RegistrySemantic proximity
Real-World Use of Rituximab in Rheumatoid Arthritis: A 3-Year Analysis from the RBSMR Biologic RegistrySemantic proximity
Select a neighboring publication to make it the new centre.